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Introduction 
Stevens-Johnson syndrome (SJS) is a rare adverse 
drug reaction characterized by epidermal 
detachment of <10% body surface area (BSA) with an 
average mortality of 1-5%. Exfoliation relates to 
extensive death of keratinocytes via apoptosis, 
mediated by CD8+ T-cells and natural killer cells [1] 
through the cytotoxic secretory protein granulysin, 
and the interaction of the death receptor-ligand pair 
Fas-FasL [2]. Nivolumab is a human immunoglobulin 
G4 monoclonal antibody directed against the 
negative immunoregulatory human cell surface 
receptor programmed cell death-1 (PD-1), with 
immune checkpoint inhibitory and antineoplastic 
activities [3]. Nivolumab results in activation of T-
cells and cell-mediated immune responses against 
tumor cells, but is not known to activate the Fas-FasL 
Abstract 
Stevens-Johnson syndrome is a rare adverse 
cutaneous drug reaction characterized by epidermal 
detachment of <10% body surface area with an 
average mortality rate of 1-5%. The mechanism of SJS 
is not fully understood. Nivolumab is a monoclonal 
antibody directed against programmed cell death-1 
protein (PD-1), a receptor with immune checkpoint 
inhibitory and antineoplastic activities. We present a 
case of SJS in a patient being treated with anti-PD-1 
therapy nivolumab for metastatic squamous cell 
carcinoma of the oropharynx. This case is unusual 
because of the severe accentuation with striking 
enhancement at his prior radiation site and in the 
cutaneous region with heavier tumor burden from 
his metastatic disease. This reaction may give insight 
to the underlying pathophysiology of SJS, 
suggesting that immune checkpoint inhibitors can 
activate T-cells to target keratinocytes and that 
external factors may be involved in creating distinct 
epitopes for T-cell recognition. We hope this case 
adds to the body of knowledge in the pathogenesis 
of Stevens-Johnson syndrome and cutaneous 
adverse events seen with checkpoint inhibitors. 
 
Figure 1. Confluent dusky violaceous to dark red erythema 
localized to the right side of his neck, right chest and right upper 
back involving 8% body surface area. 
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pathway directly [3]. We present a case of SJS 
accentuated in an area of previous radiation therapy 
in a patient being treated with nivolumab. 
 
Case Synopsis 
A 63-year-old man with a history of stage IV 
squamous cell carcinoma (SCC) of the uvula and soft 
palate was treated with neck dissection, adjuvant 
chemotherapy, and radiation treatment to the 
oropharynx and bilateral neck. He was started on 
anti-PD1 immunotherapy with nivolumab one day 
after completion of radiation. One week after the first 
nivolumab infusion, he developed a diffuse rash with 
lip crusting and conjunctival injection. He 
complained of worsening oral mucosal pain. He 
denied ocular symptoms and a full review of systems 
was otherwise unremarkable. 
He had confluent dusky violaceous to dark red 
erythema localized to the right side of his neck, chest, 
and upper back involving 8% BSA. He had 2% BSA 
desquamation, most prominent on the right 
posterior shoulder and several 1cm intact bullae with 
positive Asboe-Hansen and Nikolsky signs (Figure 1). 
In the same distribution, he had background 
poikilodermatous patches from prior radiation; his 
port was within the area of poikiloderma (Figure 2). 
On the remainder of his exam, he had a scattering of 
dusky violaceous atypical targetoid papules and 
erosions of approximately 2% BSA, a confluent 
mucositis of his upper and lower mucosal lips, and 
bilateral conjunctival injection with mucosal eyelid 
erythema. 
Three punch biopsies were obtained: from the right 
upper back (Figure 3), the right leg, and the left leg, 
all revealing a pauci-inflammatory interface process 
with numerous dyskeratotic cells, a subepidermal 
split, and areas of full thickness epidermal necrosis 
consistent with SJS. The patient recovered with 
supportive care alone, and future treatments with 
nivolumab were discontinued. 
 
 
Figure 2. Desquamation most prominent on the right posterior 
shoulder and several 1 cm intact bullae with positive Asboe-
Hansen and Nikolsky signs. In the same distribution, he had 
background poikilodermatous patches from prior radiation; his 
port was located within the area of most significant involvement 
as well as subcutaneous nodules from his metastatic squamous 
cell cancer 
 
Figure 3. A biopsy of the R upper back lesion demonstrated pauci-
inflammatory interface process with numerous dyskeratotic cells, 
subepidermal split and areas of full thickness epidermal necrosis. 
These findings are consistent with Stevens-Johnson syndrome. The 
additional two biopsies of the right and left legs demonstrated the 
same pathology. H&E, 200×. 
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Case Discussion 
In summary, we present an unusual case of SJS 
triggered by nivolumab with striking enhancement 
at the site of radiation therapy. This immune 
checkpoint inhibitor targeting PD-1 is frequently 
associated with cutaneous side effects including 
lichenoid reactions, eczema, and vitiligo [4]. This 
class of drugs has also been reported to cause 
bullous or toxic skin reactions [5]. This case adds to 
the array of cutaneous adverse effects associated 
with immune checkpoint inhibitors. 
Additionally, this case is unusual because of the 
distinct enhanced presentation at the site of 
radiation. It is unclear if this accentuation was related 
to an area of heavier tumor burden, history of 
radiation therapy, or local diffusion from the port 
infusion. This distribution could suggest a local 
fraction of T-cells being stimulated or recognizing 
distinctive epitopes induced by radiation or nearby 
cancer cells. A similar case in the literature reported 
pembrolizumab-induced SJS localized to an area 
previously treated with radiotherapy in a patient 
with metastatic sarcomatoid renal cell carcinoma [6]. 
Additionally, a case of localized bullous pemphigoid 
at the site of radiation therapy induced by a PD-1 
checkpoint inhibitor has been reported [7]. The 
sparse but scattered involvement on the remainder 
of his trunk and extremities does suggest a systemic 
component to the immune response as well. 
 
Conclusion 
This reaction may give insight to the underlying 
pathophysiology of SJS, suggesting programmed 
cell death checkpoints may be involved. Our case 
adds to the body of evidence that immune 
checkpoint inhibitors can activate T-cells to target 
keratinocytes and that external factors may be 
involved in creating distinct epitopes for T-cell 
recognition. Further work is needed to characterize 
the molecular pathways involved in the 
pathogenesis of this entity. 
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